Prevalence of Comorbidities in Patients Undergoing Oncosurgeries at Tertiary Cancer Institute in North India. (oncosurgery)

October 1, 2021 updated by: Dr Anita Kulkarni, Rajiv Gandhi Cancer Institute & Research Center, India

Prevalence of Comorbidities in Patients Undergoing Oncosurgeries at Tertiary Cancer Institute in North India

Investigators plan to study the prevalence of comorbidities in patients undergoing oncosurgeries

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Plan to study the prevalence of Coronary Artery Disease, Hypertension, Diabetes Mellitus, Hypothyroidism, History of Corona Virus infection in patients undergoing oncosurgeries.

In the Pre anesthesia checkup patients age , sex , Weight in kilograms, Height in centimeters , pulse rate, Blood Pressure will be noted and value>140/90 mmHg will be taken as hypertensive. History will be obtained about diagnosed Coronary Artery Disease , Diabetes Mellitus, Hypertension , Hypothyroidism , History of previous Corona Virus Infection (RT-PCR Test Positive) .Relevant investigations Electrocardiography and Echocardiography for assessment of Coronary Artery Disease. Fasting or Random Blood Sugar , Thyroid Function Test will be done .

Fasting Blood Sugar >126 milligram/ Decilitre and Random Blood sugar >200mg/dL will be taken as diabetic. TSH more than 5 micro IU/mL will be hypothyroid .

Study Type

Observational

Enrollment (Actual)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • India
      • Delhi, India, 110085
        • Anita Kulkarni

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult patients undergoing Oncosurgeries will be studied for prevalence of comorbidites.

Description

Inclusion Criteria: Patients undergoing Oncosurgeries Age above 40 years .

-

Exclusion Criteria:

Age below 40 years Emergency Surgery Patient Refusal

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Comorbidities in Oncosurgery patients
Prevalence of comorbidities as Coronary artery disease, Hypertension , Diabetes Mellitus,Hypothyroidism and Corona Virus Infection will be studied in patients undergoing Oncosurgeries.
Other: To study comorbidities in patients undergoing Oncosurgeries
In the Preoperative Anaesthesia checkup we will study prevalence of comorbidities as Coronary artery Disease, Hypertension, Diabetes Mellitus , Hypothyroidism and prior Corona Virus Infection in patients undergoing Oncosurgeries

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To study Coronary Artery disease in patients undergoing Oncosurgeries
Time Frame: 60 days

Electrocardiography and Echocardiography will be performed.

Investigators will measure Blood Pressure , Blood Sugar , Thyroid Function Test and previous Corona Virus Infection
60 days
To study Diabetes Mellitus in patients undergoing Oncosurgeries.
Time Frame: 60days
Random Blood Sugar in milligram/Decilitre will be measured.
60days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To study Hypothyroidism in patients undergoing Oncosurgeries
Time Frame: 60 days
Thyroid Stimulating Hormone (TSH) in micro IU / millilitre will be measured.
60 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Rajiv Gandhi Cancer Institute & Research Center, India

Investigators

  • Principal Investigator: Anita Kulkarni, MD, Rajiv Gandhi Cancer Institute and RC , Delhi, INDIA

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2021

Primary Completion (Actual)

August 31, 2021

Study Completion (Actual)

August 31, 2021

Study Registration Dates

First Submitted

August 15, 2021

First Submitted That Met QC Criteria

September 1, 2021

First Posted (Actual)

September 9, 2021

Study Record Updates

Last Update Posted (Actual)

October 4, 2021

Last Update Submitted That Met QC Criteria

October 1, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • RGCI \ MK 1967

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Comorbidities and Coexisting Conditions

Clinical Trials on To study comorbidities in patients undergoing Oncosurgeries

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe